Benzinga · Aug 11, 2026
Aura Biosciences May Offer Securities Up To $500M Aggregate; May Sell Up To $200M Common Stock Under Sales Agreement With Jefferies
- Sec Filing
NASDAQ · AURA
Aura Biosciences, Inc.
Healthcare · Biotechnology
$7.65
Down-$0.05 (-0.65%)
Updated Aug 14, 2026, 3:43 PM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 413.26M
- P/E ratio
- -3.72
- Dividend yield
- 0.00%
- 52-week range
- $5.31 – $9.54
- Volume
- 1.05M
- Avg. volume
- 260.47K
Price performance
AURA price history
1M range · 21 trading sessions · Daily adjusted prices
AURA closed at $7.65 after 21 trading sessions, up 11.03% for the selected period.
- Last close
- $7.65
- Period change
- +11.03%
- Period low
- $6.82
- Period high
- $8.04
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $7.635 | $8.00 | $7.445 | $7.65 | 1.05M |
| Aug 12, 2026 | $7.77 | $7.77 | $7.07 | $7.75 | 901.98K |
| Aug 11, 2026 | $7.55 | $8.20 | $7.31 | $8.04 | 1.01M |
| Aug 10, 2026 | $7.95 | $8.02 | $7.61 | $7.70 | 499.25K |
| Aug 7, 2026 | $7.81 | $8.00 | $7.72 | $7.99 | 538.28K |
| Aug 6, 2026 | $7.24 | $7.74 | $7.20 | $7.72 | 577.51K |
| Aug 5, 2026 | $7.18 | $7.29 | $6.96 | $7.18 | 314.87K |
| Aug 4, 2026 | $7.07 | $7.23 | $7.04 | $7.15 | 277.52K |
| Aug 3, 2026 | $7.01 | $7.05 | $6.80 | $7.04 | 422.23K |
| Jul 31, 2026 | $7.01 | $7.09 | $6.85 | $7.01 | 294.06K |
| Jul 30, 2026 | $7.09 | $7.16 | $6.93 | $7.11 | 292.93K |
| Jul 29, 2026 | $7.03 | $7.135 | $6.82 | $7.01 | 481.24K |
| Jul 28, 2026 | $7.17 | $7.20 | $6.965 | $7.05 | 439.33K |
| Jul 27, 2026 | $7.10 | $7.31 | $7.05 | $7.16 | 252.14K |
| Jul 24, 2026 | $7.115 | $7.23 | $6.985 | $7.05 | 325.84K |
| Jul 23, 2026 | $6.94 | $7.22 | $6.94 | $7.20 | 230.7K |
| Jul 22, 2026 | $6.99 | $7.059 | $6.92 | $7.01 | 412.23K |
| Jul 21, 2026 | $6.82 | $7.06 | $6.71 | $7.03 | 307.55K |
| Jul 20, 2026 | $7.00 | $7.125 | $6.78 | $6.82 | 420.99K |
| Jul 17, 2026 | $6.74 | $7.03 | $6.73 | $6.99 | 408.71K |
| Jul 16, 2026 | $6.92 | $7.00 | $6.73 | $6.89 | 339.59K |
Latest AURA news
The latest Smart Investors Daily articles mentioning AURA.
Stock researchCompany · Overview
AURA research
Overview
Company profile and research snapshot.
Company profile
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $22.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 29, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 30, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 26, 2025 | Evercore ISI Group | Outperform | — |
| Aug 13, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 11, 2026
HC Wainwright & Co. Maintains Buy on Aura Biosciences, Lowers Price Target to $18
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Aura Biosciences (NASDAQ:AURA) with a Buy and lowers the price target from $24 to $18.
Benzinga · Aug 11, 2026
Aura Biosciences Q2 EPS $(0.48) Misses $(0.38) Estimate
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.38) by 29.73 percent. This is a 2.13 percent decrease over losses of $(0.47) per share
Benzinga · Jul 24, 2026
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
US stock futures higher, Deckers Outdoor shares fall after reporting Q1 results. Other stocks also down in pre-market trading. Photo via Shutterstock.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
